Find Clinical Trials

September 14, 2022 in Breast

BR005

BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the…
Read More
August 16, 2022 in Breast

S2007

S2007: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases (NCT 04647916)
Read More
July 11, 2022 in Breast

S1706

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
Read More
July 11, 2022 in Breast

S1703

S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Read More
July 1, 2022 in Breast

MA-39

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)
Read More
June 30, 2022 in Breast

FB-13

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
Read More
June 30, 2022 in Breast

EAQ201

EAQ201: COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation (NCT 05076266)
Read More
June 30, 2022 in Breast

EA1183

EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE
Read More
June 30, 2022 in Breast

EA1181

EA1181: (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
Read More
June 30, 2022 in Breast

BR007

BR007: A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ? 18 Breast Cancer
Read More
June 30, 2022 in Breast

B-61 lidERA (GO42784)

B-61 lidERA (GO42784) A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety Of Adjuvant GDC9545 Compared with Physician's Choice of Adjuvant Endocrine Monotherapy In Patients With ER+,…
Read More
June 30, 2022 in Breast

AFT-25 (COMET)

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS (COMET)
Read More
June 29, 2022 in Breast

A011801

A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and…
Read More